$7.72
-0.20 (-2.53%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IBRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
78 interventional · 1 observational · 2 expanded access · 24 with posted results
Held by 14 tracked-famous managers (D. E. Shaw & Co., Inc., TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, Squarepoint Ops LLC, +9 more) · FINRA short interest 14.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)NCT05981131observationalObtain Long Term Follow-Up data to be summarized using descriptive statistics | — | Active, not recruiting | Drug: N803 plus Bacillus Calmette-Guerin (BCG) | Non Muscle Invasive Bladder Cancer | 6 | 2033-08-30 | in 2,568 d | 2026-04-29 |
| Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard ChemoradiationNCT07628062Progression-Free Survival (PFS)Randomized · Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: Nogapendekin Alfa Inbakicept (NAI), Nab-Paclitaxel, Cisplatin · Biological: hAd5-HPV Vaccine (IBRX-042) · Radiation: De-Intensified IMRT, Standard of Care IMRT | HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer | 70 | 2030-12-31 | in 1,595 d | 2026-06-04 |
| N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaNCT06061809Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Bevacizumab, PD-L1 t-haNK, N-803 · Device: Tumor Treating Fields (TTFields, 200 kHz) | Glioblastoma | 34 | 2029-12-31 | in 1,230 d | 2026-07-01 |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667ORR, defined as Investigator-assessed CR + PR per RECIST v1.1.Non-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab | Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer | 40 | 2029-08-31 | in 1,108 d | 2026-01-14 |
| Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint InNCT06745908Compare Overall Survival between the experimental and control armsRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: N-803, Tislelizumab, Docetaxel, Prior failed checkpoint inhibitor | NSCLC Stage IV | 507 | Sep 2028 | ≤ 773 d | 2026-07-27 |
| ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCGNCT06800963The primary endpoint is to assess safety as measured by the incidence and severity of adverse events.Open-label · Treatment | Phase 1/2 | Recruiting | Biological: Intravesical Recombinant Mycobacterium (rMBCG) | NMIBC | 40 | Feb 2028 | ≤ 559 d | 2026-03-27 |
| Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNCT07477366ORR in accordance with Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC)Open-label · Treatment | Phase 2 | Not yet recruiting | Biological: CD19 t-haNK- IV Administration · Drug: N-803, rituximab | Relapsed B-Cell Non-Hodgkin Lymphoma | 20 | Dec 2027 | ≤ 499 d | 2026-03-17 |
| Study for Participants With Relapsed/Refractory Non-Hodgkin LymphomaNCT06334991Overall safety evaluation in combining CD19 t haNK as a single agent with rituximabOpen-label · Treatment | Phase 1 | Active, not recruiting | Biological: CD19 t-haNK | Non-Hodgkin Lymphoma Refractory/ Relapsed | 20 | Oct 2027 | ≤ 438 d | 2026-07-10 |
| IBRX-042 In Participants With HPV-Associated TumorsNCT05976828Determine the maximum tolerated dose of IBRX-042Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: IBRX-042 | HPV-Related Carcinoma | 12 | 2027-09-02 | in 379 d | 2025-10-20 |
| NAI for Sepsis With Persistent LymphopeniaNCT0757855828-day all-cause mortality rateRandomized · Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: Nogapendekin alfa inbakicept (NAI) · Other: Standard of Care (SOC) | Sepsis, Septic Shock, Lymphopenia, Immunosuppression, Critical Illness | 50 | 2027-08-03 | in 349 d | 2026-05-11 |
| Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic CancerNCT07488884Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: Nogapendekin Alfa Inbakicept (N803), Sotevtamab, Zabadinostat (CXD101), Nab paclitaxel / gemcitabine | Pancreatic Cancer Resectable, Pancreatic Cancer | 30 | 2027-06-01 | in 286 d | 2026-04-29 |
| A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerNCT06710288Evaluate Progression Free Survival (PFS)Open-label · Treatment | Phase 2 | Recruiting | Drug: Gemcitabine · Biological: N-803, M-CENK | Platinum-resistant Ovarian Cancer | 20 | May 2027 | ≤ 285 d | 2026-07-01 |
| Study of Relapsed/ Refractory B-cell Non- Hodgkin LymphomaNCT07125872Primary Endpoints( Efficacy)Open-label · Treatment | Phase 2 | Recruiting | Biological: CD19 t-haNK- IV Administration | Relapsed B-Cell Non Hodgkin Lymphoma | 20 | 2027-05-25 | in 279 d | 2026-05-04 |
| Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNCT06829823Efficacy of Arms A and B at Month 3 and Month 6Randomized · Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: N-803 and BCG, N-803 and Gemcitabine | Non-muscle Invasive Bladder Cancer (NMIBC) | 20 | Nov 2026 | ≤ 103 d | 2025-10-16 |
| A Study to Assess Anktiva in Patients With Long Covid-19.NCT07108036Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.Open-label · Treatment | Phase 2 | Recruiting | Drug: N-803 (IL-15 Superagonist) | Long COVID | 20 | Oct 2026 | ≤ 73 d | 2026-05-11 |
| A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerNCT02138734Complete Response (CR) RateRandomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Biological: BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation) | Non-muscle Invasive Bladder Cancer | 369 | 2026-09-30 | in 42 d | 2026-03-31 |
| A Study to Examine Anktiva for the Treatment of COVID-19.NCT07123727Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.Open-label · Treatment | Phase 2 | Recruiting | Drug: Anktiva | Long COVID, Long COVID Syndrome, Long Covid 19 | 40 | Jul 2026 | — | 2026-05-13 |
| QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid TumorsNCT04898543Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to apheresis.Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B) · Other: Apheresis collection of MNCs (part A) | Metastatic Solid Tumor | 50 | 2026-05-31 | — | 2025-12-11 |
| Study for Subjects With Relapsed/Refractory Non- Hodgkin LymphomaNCT05618925Primary Outcome MeasuresRandomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: N803, Cyclophosphamide, Fludarabine, Rituximab · Biological: CD19t-haNK suspension | Non Hodgkin's Lymphoma Refractory/Relapsed | 20 | 2026-05-15 | — | 2026-04-01 |
| Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerNCT04390399Progression Free Survival (PFS)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Biological: N-803, PD-L1 t-haNK · Drug: Aldoxorubicin HCl, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Irinotecan liposome · Procedure: SBRT | Pancreatic Cancer | 328 | 2025-10-13actual | — | 2025-12-15 |
| QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerNCT03022825Complete ResponseOpen-label · Treatment | Phase 2/3 | Active, not recruiting | Drug: N-803 and BCG, N-803 | Bladder Cancer | 190 | 2024-10-01actual | — | 2025-10-16 |
| ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder CancerNCT07551544Clinical Complete Response (CR) RateRandomized · Open-label · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Sponsor decision | Biological: BCG (50 mg) plus ANKTIVA (400 µg), BCG (50 mg) | NMIBC | 0 | May 2032 | ≤ 2,112 d | 2026-05-19 |
| Immunotherapy Before and After SurgeryNCT06765902Event-free survival (EFS)Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Study was redeveloped into a new protocol | Drug: N-803, ETBX-071, M-CENK | High-risk Prostate Cancer | 0 | 2031-01-31 | in 1,626 d | 2026-05-05 |
| Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.NCT06765954Complete Pathologic Response (CPR) after pre-radiation immunotherapy.Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Study was redeveloped into a new protocol | Drug: N-803 (IL-15 Superagonist), ETBX-071 (PSA-based Oncolytic Virus), M-CENK (Activated NK Cells) · Radiation: External Beam Radiation Therapy (EBRT), Androgen Deprivation Therapy (ADT), Post-radiation immunotherapy | High-risk Prostate Cancer | 0 | 2031-01-31 | in 1,626 d | 2026-05-05 |
| Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLCNCT07524257Progression-Free Survival (PFS) by BICR (RECIST v1.1)Randomized · Open-label · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Sponsor decision | Drug: Drug: Nogapendekin alfa inbakicept (NAI), Pembrolizumab, Cisplatin or Carboplatin, Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous), Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous), Pemetrexed (nonsquamous) | NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC | 0 | 2029-05-15 | in 1,000 d | 2026-06-22 |
| Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired PneumoniaNCT0749287528-day all-cause mortalityRandomized · Single-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: New protocol developed | Biological: Nogapendekin alfa inbakicept (NAI), agenT-797 | Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia, Immunoparalysis | 0 | 2029-04-15 | in 970 d | 2026-05-08 |
| Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)NCT0749288828-day all-cause mortalityOpen-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: New protocol developed | Drug: Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) | Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults | 0 | 2026-11-15 | in 88 d | 2026-05-08 |
| A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic LeukemiaNCT07556757Evaluate safety of CD19 t-haNK as a single agent in participants with selected CD19+ relapsed B-ALL.Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug | Drug: CD19 t-haNK | B-ALL, Leukemia | 4 | 2026-07-01actual | — | 2026-08-19 |
| Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerNCT03520686Progression Free Survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov within 1 year of the primary completion date. | Drug: NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab, NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI, Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI, Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI, Carboplatin + Nab-paclitaxel + Atezolizumab + NAI, Pembrolizumab, Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab, Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab, Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab, Carboplatin and Nab-paclitaxel plus Atezolizumab, Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel | Non Small Cell Lung Cancer | 102 | 2025-10-13actual | — | 2026-05-26 |
| HCW9218 for Advanced Pancreatic CancerNCT05304936Occurrence of Adverse Events and Treatment-Related Adverse EventsOpen-label · Treatment | Phase 1/2 | Completed | Drug: HCW9218, Gemcitabine (GEM), Nab-paclitaxel | Advanced Pancreatic Carcinoma | 21 | 2025-02-15actual | — | 2026-04-15 |
| Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By ApheresisNCT06040918Incidence of serious adverse events (SAEs) and overall adverse events (AEs) coded in MedDRAOpen-label · Other | Phase 1 | Completed | Drug: N-803 | Healthy Subjects | 10 | 2024-09-03actual | — | 2025-10-14 |
| THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 VaccinesNCT05370040results2024-05-01Phase 1 Safety - Incidence of MAAEs Through 1 WeekRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan: part 1 ↗ · Study Protocol and Statistical Analysis Plan: part 2 ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Discontinued prior to enroll in Phase 2 | Biological: AAHI-SC2 Vaccine, AAHI-SC3 Vaccine, EUA or approved vaccine | COVID-19 | 60 | 2024-03-11actual | — | 2025-03-11 |
| A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior TherapiesNCT04927884results2024-06-12Number of Participants With Treatment Emergent Adverse EventsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: low enrollment | Biological: N-803, PD-L1 t-haNK · Drug: Sacituzumab Govitecan-Hziy, Cyclophosphamide | Advanced Triple Negative Breast Cancer | 3 | 2022-09-13actual | — | 2024-06-12 |
| COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African AdultsNCT04710303results2024-11-15Number of Participants With Medically Attended Adverse Events (MAAE)Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: hAd5-S-Fusion+N-ETSD vaccine | Covid19 | 41 | 2022-08-02actual | — | 2024-11-15 |
| COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USANCT04732468results2024-10-15Incidence of Solicited Local Reactogenicity AEsNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: The study was terminated early due to low enrollment. | Biological: hAd5-S-Fusion+N-ETSD (Suspension for injection) · Drug: hAd5-SFusion+ N-ETSD (Oral capsule) | Covid19 | 28 | 2022-07-11actual | — | 2024-10-15 |
| A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIALNCT06022224results2024-06-07Number of Participants With Adverse EventsRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: There were no participants enrolled into Phase 3 portion of the study because the study was prematurely terminated. | Biological: hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline) | COVID-19 | 35 | 2022-06-23actual | — | 2024-06-07 |
| COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy VolunteersNCT04591717Incidence of MAAEs and SAEsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: hAd5-S-Fusion+N-ETSD vaccine | COVID-19 | 34 | 2022-04-20actual | — | 2023-02-28 |
| COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based VaccinesNCT04843722Phase 1 Safety: Incidence of MAAEs and SAEsRandomized · Triple-masked · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: The sponsor has changed the development plans which is not for safety reasons. | Biological: hAd5-S-Fusion+N-ETSD vaccine | Covid19 | 0 | Dec 2021 | — | 2025-02-21 |
| COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based VaccinesNCT04845191Phase 1 Safety: Incidence of MAAEs and SAEsRandomized · Triple-masked · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: The sponsor has changed the development plans which is not for safety reasons. | Biological: hAd5-S-Fusion+N-ETSD vaccine | Covid19 | 0 | Dec 2021 | — | 2025-02-21 |
| QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint TherapyNCT03853317results2024-08-09Number of Participants With Adverse EventsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Not meeting recruitment goal | Biological: Avelumab, N-803, haNK™ | Merkel Cell Carcinoma | 9 | 2021-09-29actual | — | 2024-08-09 |
| QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell LymphomaNCT04052061MTD or HTD and RP2D.Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: CD19 t-haNK | Diffuse Large B Cell Lymphoma, Large-cell Lymphoma, Lymphoma, B-Cell, Lymphoma | 0 | 2021-09-18 | — | 2025-02-21 |
| QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid CancersNCT04050709MTD or HTD and RP2D.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: PD-L1 t-haNK | Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor | 16 | 2021-03-30actual | — | 2026-04-01 |
| QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.NCT03387085results2024-08-09Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention | Drug: Aldoxorubicin HCl, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel · Biological: N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab · Procedure: SBRT | Triple Negative Breast Cancer | 9 | 2020-09-11actual | — | 2024-08-09 |
| Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical VentilationNCT04397796results2024-09-05Number of Participants With Adverse Events Within 30 Days of RandomizationRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. | Biological: BM-Allo.MSC, Placebo | COVID | 4 | 2020-09-06actual | — | 2024-09-05 |
| QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.NCT03647423Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.Randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: Aldoxorubicin Hydrochloride, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK · Drug: Avelumab, Cetuximab, Cyclophosphamide · Radiation: SBRT | Chordoma, Unresectable Malignant Neoplasm | 0 | 2020-08-31 | — | 2025-02-21 |
| Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19NCT04385849results2024-09-05Number of Participants With Adverse EventsRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. | Biological: N-803 · Other: Saline | COVID-19 | 1 | 2020-07-25actual | — | 2024-09-05 |
| QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineNCT03554109Pathological Complete Response RateRandomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Trial not initiated | Drug: Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl, nab-Paclitaxel, Avelumab, Cyclophosphamide, Doxorubicin HCL, paclitaxel · Biological: ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, ALT-803, haNK | Triple Negative Breast Cancer (TNBC) | 0 | Jun 2020 | — | 2025-02-21 |
| QUILT-3.088: NANT Pancreatic Cancer VaccineNCT03563144Progression-Free SurvivalRandomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Trial not initiated | Drug: Gemcitabine, Nab-paclitaxel, Aldoxorubicin HCl, Avelumab, Bevacizumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Oxaliplatin · Biological: ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK | Metastatic Pancreatic Cancer | 0 | 2019-12-30 | — | 2025-02-21 |
| QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineNCT03563170Incidence of treatment-emergent AEs and SAEs, graded using the NCI CTCAE Version 4.03Randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Enrollment not initiated | Biological: ETBX-011, GI-4000, haNK for infusion, avelumab, Aldoxorubicin hydrochloride, ETBX-051, ETBX-061, GI-6207, GI-6301, N-803 · Drug: Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, Sorafenib, Cetuximab · Procedure: SBRT | Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent | 0 | 2019-08-23actual | — | 2021-03-18 |
| QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid TumorsNCT03027128results2024-11-20Determination of Maximum Tolerated Dose (MTD) or Highest Tested Dose (HTD).Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: haNK™ for Infusion | Solid Tumor | 6 | 2019-05-06actual | — | 2024-11-20 |
| QUILT 3.071: NANT Colorectal Cancer (CRC) VaccineNCT03563157results2024-12-11Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: low enrollment | Biological: Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK · Drug: Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib · Procedure: SBRT | Colorectal Cancer Metastatic, mCRC | 2 | 2019-04-21actual | — | 2024-12-11 |
| QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedNCT03387111results2024-08-05Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention | Drug: Aldoxorubicin HCl, Avelumab, bevacizumab, Capecitabine, Cetuximab, Cisplatin, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Necitumumab · Biological: ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, N-803 · Procedure: SBRT | Squamous Cell Carcinoma | 4 | 2019-04-17actual | — | 2024-08-05 |
| QUILT-3.080: NANT Pancreatic Cancer VaccineNCT03586869results2024-08-27Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention | Drug: Aldoxorubicin HCl, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Oxaliplatin · Biological: ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, bevacizumab, Avelumab · Procedure: SBRT | Pancreatic Cancer | 3 | 2019-04-17actual | — | 2024-08-27 |
| QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyNCT03197584Incidence of treatment-emergent adverse events (AEs) and serious AE (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: Avelumab, Bevacizumab, ALT-803, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6301, haNK® · Drug: Capecitabine, Cyclophosphamide, 5-fluorouracil, Fulvestrant, Leucovorin, Paclitaxel, omega-3 acid ethyl esters, Oxaliplatin · Radiation: Stereotactic Body Radiation Therapy | Ovarian Cancer | 0 | Feb 2019 | — | 2025-02-21 |
| QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyNCT03167164Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: Avelumab, Bevacizumab, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK · Drug: Capecitabine, Cisplatin, Cyclophosphamide, 5-fluorouracil, Leucovorin, nab-Paclitaxel, omega-3-acid ethyl esters · Radiation: Stereotactic Body Radiation Therapy | Merkel Cell Carcinoma | 0 | Jan 2019 | — | 2025-02-21 |
| QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyNCT03167177Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: Avelumab, Bevacizumab, Nivolumab, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-6207, GI-6301, haNK · Drug: Capecitabine, Cisplatin, Cyclophosphamide, 5-fluorouracil, Leucovorin, nab-paclitaxel, omega-3-acid ethyl esters · Radiation: Stereotactic Body Radiation Therapy | Melanoma | 0 | Jan 2019 | — | 2025-02-21 |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsNCT03169738Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: avelumab, Bevacizumab, nivolumab, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK · Drug: Capecitabine, Cisplatin, cyclophosphamide, 5-Fluorouracil (5-FU), fulvestrant, leucovorin, nab paclitaxel, Lovaza, Oxaliplatin · Radiation: Stereotactic Body Radiation Therapy | Non-small Cell Lung Cancer | 0 | Jan 2019 | — | 2025-02-21 |
| QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyNCT03169764Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: Avelumab, Bevacizumab, Cetuximab, nivolumab, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK · Drug: Capecitabine, Cisplatin, cyclophosphamide, 5-Fluorouracil (5-FU), fulvestrant, leucovorin, nab-paclitaxel, Lovaza · Radiation: Stereotactic Body Radiation Therapy | Head and Neck Squamous Cell Carcinoma | 0 | Jan 2019 | — | 2025-02-24 |
| QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCNCT03169777Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: avelumab, bevacizumab, cetuximab, nivolumab, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK · Drug: capecitabine, Cyclophosphamide, 5-Fluorouracil (5-FU), fulvestrant, leucovorin, nab paclitaxel, Lovaza, oxaliplatin · Radiation: Stereotactic Body Radiation Therapy | Colorectal Cancer | 0 | Jan 2019 | — | 2025-02-21 |
| QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLNCT03169790Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: avelumab, bevacizumab, ALT-803, ETBX-061, haNK · Drug: capecitabine, cyclophosphamide, 5-Fluorouracil (5-FU), leucovorin, nab-paclitaxel, Lovaza, Oxaliplatin, rituximab · Radiation: Stereotactic Body Radiation Therapy | Non Hodgkin Lymphoma | 0 | Jan 2019 | — | 2025-02-24 |
| QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyNCT03175666Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: avelumab, bevacizumab, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK · Drug: capecitabine, cisplatin, cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-paclitaxel, Lovaza · Radiation: Stereotactic Body Radiation Therapy | Triple Negative Breast Cancer | 0 | Jan 2019 | — | 2025-02-21 |
| QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyNCT03197571Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: avelumab, bevacizumab, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK · Drug: capecitabine, cisplatin, cyclophosphamide, 5Fluorouracil (5-FU), fulvestrant, leucovorin, nab-paclitaxel, Lovaza · Radiation: Stereotactic Body Radiation Therapy | Urothelial Carcinoma | 0 | Jan 2019 | — | 2025-02-21 |
| QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyNCT03387098results2024-05-22Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs), Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention | Drug: Aldoxorubicin HCl, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin · Biological: ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab · Procedure: SBRT | Pancreatic Cancer | 4 | 2018-09-12actual | — | 2024-05-22 |
| QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerNCT03574649Relapse-free survival ( RFS)Randomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Trial not initiated | Drug: Nab-paclitaxel, Cisplatin, 5Fluorouracil, Cyclophosphamide, Aldoxorubicin, Avelumab, ALT-803, Docetaxel, carboplatin · Biological: ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6301, haNK | Non Small Cell Lung Cancer | 0 | Aug 2018 | — | 2025-02-21 |
| QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyNCT03329248results2024-12-12Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention | Biological: ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab · Drug: Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin · Procedure: SBRT | Pancreatic Cancer | 6 | 2018-08-13actual | — | 2024-12-12 |
| Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue SarcomaNCT02235701results2024-05-29Number of Adverse Events in ParticipantsRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: 170 mg/m2 aldoxorubicin, 250 mg/m2 aldoxorubicin | Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma | 70 | 2018-05-01actual | — | 2024-05-29 |
| QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)NCT02465957results2024-05-02Number of Participants With Progression Free Survival Rate at 4 MonthsNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminated | Biological: aNK (NK-92), aNK (NK-92) + N-803 | Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma | 7 | 2018-03-19actual | — | 2024-05-02 |
| QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyNCT03136406results2024-06-11Number of Participants With Adverse EventsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention | Drug: Cyclophosphamide, Oxaliplatin, Capecitabine, 5-Fluorouracil, Leucovorin, nab-paclitaxel · Biological: bevacizumab, avelumab, ALT-803, aNK for Infusion, ETBX-011, GI-4000 | Pancreatic Cancer | 3 | 2017-11-22actual | — | 2024-06-11 |
| Phase 3 Study to Treat Patients With Soft Tissue SarcomasNCT02049905results2024-06-13Progression-Free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide) | Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma | 433 | May 2017actual | — | 2024-06-13 |
| Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung CancerNCT02200757results2024-06-25Progression-Free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Aldoxorubicin, Topotecan | Metastatic Small Cell Lung Cancer | 135 | 2017-05-15actual | — | 2024-06-25 |
| Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid TumorsNCT02235688Safety MeasuresNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: aldoxorubicin, aldoxorubicin, aldoxorubicin, gemcitabine | Metastatic Solid Tumors | 30 | Jan 2017actual | — | 2022-02-10 |
| Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With GlioblastomaNCT02014844results2024-05-29Objective Response Rate (Complete Response and Partial Response)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: 250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicin | Glioblastoma | 28 | Dec 2016actual | — | 2024-05-29 |
| A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's SarcomaNCT02029430results2024-06-11Objective Response RateRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: 50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin | Kaposi's Sarcoma, HIV Positive, AIDS | 15 | 2016-04-25actual | — | 2024-06-11 |
| QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid LeukemiaNCT00900809Determine the safety / maximum tolerated dose of Neukoplast™ (NK-92 cell line for clinical use) in patients with refractory or relapsed acute myeloid leukemiaOpen-label · Treatment | Phase 1 | Completed | Biological: Neukoplast™ (NK-92) | Acute Myeloid Leukemia | 7 | 2015-06-02actual | — | 2022-04-05 |
| Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid TumorsNCT01706835PharmacokineticsOpen-label · Treatment | Phase 1 | Completed | Drug: aldoxorubicin | Advanced Solid Tumors | 18 | Dec 2014actual | — | 2022-02-10 |
| Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid TumorsNCT01673438Safety and TolerabilityOpen-label · Treatment | Phase 1 | Completed | Drug: aldoxorubicin | Advanced Solid Tumor | 15 | Apr 2014actual | — | 2022-02-10 |
| Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue SarcomaNCT01514188results2024-05-29Progression-free SurvivalRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: INNO-206, Doxorubicin | Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma | 126 | 2014-04-09actual | — | 2024-05-29 |
| Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic CancerNCT01580397results2024-06-06Objective Response RateOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: INNO-206 | Pancreatic Ductal Adenocarcinoma | 15 | 2013-05-13actual | — | 2024-06-06 |
| Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid TumorsNCT01337505SafetyOpen-label · Treatment | Phase 1 | Completed | Drug: INNO-206 | Malignant Solid Tumour | 24 | Sep 2012actual | — | 2022-02-10 |
| ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder CancerNCT06810141expanded access | — | Available | Biological: rMBCG | NMIBC | — | — | — | 2026-05-14 |
| Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation TherapyNCT06956547expanded access | — | Available | Drug: nogapendekin-alfa inbakicept | Lymphopenia | — | — | — | 2025-10-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19